STRATEC SE

Quarterly Report • Oct 28, 2015

Profile

STRATEC develops and manufactures fully automated analyzer systems based on its own patented technologies for its partners in the fields of clinical diagnostics and biotechnology. STRATEC's partners are mostly global players operating in the in-vitro diagnostics industry. These companies market STRATEC's systems under their own names, in general together with their own reagents, as system solutions to laboratories, blood banks, and research institutes around the world.

Contents

Highlights / Key Group Figures at a Glance	03
Letter from the Board of Management	04
Interim Group Management Report	05
Consolidated Balance Sheet as of September 30, 2015	09
Consolidated Statement of Comprehensive Income for the Period from July 1 to September 30, 2015	11
Consolidated Statement of Comprehensive Income for the Period from January 1 to September 30, 2015	12
Consolidated Statement of Changes in Equity for the Period from January 1 to September 30, 2015	13
Consolidated Cash Flow Statement for the Period from January 1 to September 30, 2015	15
Notes to the Group Interim Report for the Period from January 1 to September 30, 2015	16
Additional Information	19

Highlights

Sales of 1 107.2 million in 9M/2015 (+1.8%; 9M/2014: 1 105.3 million)

EBIT of 1 19.2 million in 9M/2015 (+8.8%; 9M/2014: 1 17.7 million*)

EBIT margin of 17.9% in 9M/2015 (+110 basis points; 9M/2014: 16.8%*)

EBIT margin for 2015: Expected to be above 9M/2015 margin

Earnings per share of 1 1.35 in 9M/2015 (+8.9%; 9M/2014: 1 1.24*)

Key Group Figures at a Glance

in D thousands	01.01. –09.30.2015	01.01. –09.30.2014	Change
Sales	107,200	105,278	+1.8%
EBIT	19,235	17,685*	+8.8%
EBIT margin (%)	17.9	16.8 *	+110 bps
Consolidated net income	15,916	14,627 *	+8.8%
Earnings per share (D )	1.35	1.24 *	+8.9%
No. of employees (09.30.)	573	554	+3.4%

in D thousands	09.30.2015	12.31.2014	Change
Shareholders' equity	123,744	112,051	+10.4%
Total assets	153,832	137,748	+11.7%
Equity ratio (%)	80.4	81.3	-90 bps

bps = basis points

* 2014 figure adjusted to exclude a one-off negative item resulting from the recognition in the first quarter of expenses for the remaining years of the term of a management board contract for a retired member of the Board of Management. Unadjusted EBIT for the first nine months of 2014 amounted to 1 17.0 million; the corresponding EBIT margin amounted to 16.2%, consolidated net income to 1 14.2 million and earnings per share to 1 1.20. The actual amount of the aforementioned expense item may differ at the time of payment from the amounts presented here.

Letter from the Board of Management

Dear Shareholders, Dear Partners and Friends of STRATEC,

STRATEC continued its positive operating performance in the third quarter, reporting a slight increase in sales and a significant improvement in margin development at the group level. We continue to work on numerous projects and on achieving significant milestones that will play a key role not only in terms of the technological development of our analyzer systems, but also for STRATEC's further strategic development. Our planning here focuses above all on extending our value chain, on the new and further development of platform systems, and on additional external growth.

A glance at the first nine months of 2015 shows that sales grew year-on-year by 1.8% to 1 107.2 million and that we boosted our EBIT margin from 16.8% in the previous year to 17.9%. As a result, consolidated net income grew by 8.8% to 1 15.9 million and earnings per share increased by 8.9% to 1 1.35.

For 2015 as a whole, we expect to achieve sales growth on a par with that seen most recently and also aim to increase our profitability to a level above that seen in the first nine-months.

Some of our partners are currently observing a weakening in demand in certain growth regions that could lead to lower volumes of analyzer systems being placed. By focusing on innovative technologies and growth segments within our industry, we believe we are well placed to cope with such fluctuations in the market. Furthermore, we are continually stocking our development pipeline, a factor that generally leads to further market launches in subsequent years and to additional growth momentum. Due not least to this, we are confident that we will be able to report further growth, create additional jobs, and further extend our position as a leading provider of innovative solutions to the diagnostics and healthcare industry in the years ahead.

To support our growth our UK team will be moving to larger premises, most likely at the turn of the year. Our construction activities in Romania and Switzerland are progressing on schedule and we expect to move into both new buildings in the first half of 2016.

We would like to thank you sincerely for the trust you have placed in our work.

Birkenfeld, October 2015

The Board of Management of STRATEC Biomedical AG

Marcus Wolfinger Dr. Robert Siegle Dr. Claus Vielsack

Interim Group Management Report

Report on the Earnings, Financial and Net Asset Position

STRATEC increased its sales by 1.8% to 1 107.2 million in the first nine months of the 2015 financial year (previous year: 1 105.3 million). The gross profit (gross profit on sales) grew to 1 39.6 million (37.0% of sales), up by 1 3.9 million compared with the previous year's figure of 1 35.8 million (34.0% of sales). This growth was chiefly driven by efficiency enhancements and by the robust performance of the spare parts and services business.

Gross development expenses rose by 1 1.4 million to 1 15.8 million, of which 1 10.2 million were capitalized. Sales-related expenses increased from 1 4.2 million to 1 5.0 million, while administration expenses remained constant at 1 8.2 million.

Due to lower amortization of intangible assets, depreciation and amortization reduced from 1 5.8 million in the previous year to 1 4.1 million. At 1 19.2 million, EBIT was 1 2.2 million, or 12.9%, ahead of the previous year's figure (which included a one-off charge due to the termination of a management board contract). This resulted in an EBIT margin of 17.9% (previous year: 16.2%). Net financial expenses amounted to 1 0.2 million (previous year: 1 -0.1 million). The tax result amounted to 1 3.5 million. STRATEC can thus report consolidated net income of 1 15.9 million for the period under report (previous year: 1 14.2 million). Earnings per share amounted to 1 1.35 (previous year: 1 1.20).

Driven in particular by the progress made with construction activity in Switzerland, property, plant and equipment increased year-on-year by 1 1.8 million to 1 17.8 million. Despite ongoing pleasing levels of demand for analyzer systems and a full development pipeline, inventories rose only slightly from 1 18.1 million in the previous year to 1 20.0 million. Mainly as a result of higher income tax receivables, receivables and other assets grew by 1 3.5 million to 1 28.0 million.

The equity ratio amounted to 80.4%. The Group has reduced its non-current financial liabilities from 1 4.5 million in the previous year to 1 3.9 million and its current financial liabilities from 1 2.5 million in the previous year to 1 1.4 million. The increase in trade payables was driven by higher procurement volumes for raw materials and supplies. The marked increase in prepayments for development services is reported within other current liabilities.

Given the higher income tax payment, the cash flow from operating activities decreased from 1 25.7 million to 1 21.5 million. At 1 5.3 million, investments fell only slightly short of the previous year's figure. Even though an amount of 1 8.2 million was distributed as dividends (previous year: 1 7.1 million), cash and cash equivalents nevertheless increased from 1 46.6 million to 1 54.7 million as of September 30, 2015.

Changes in the Business Environment and Implications for STRATEC

Macroeconomic framework: The International Monetary Fund (IMF) has issued a further downward correction in the global economic forecast published in its half-yearly World Economic Outlook. For 2015, the IMF now expects to see growth of 3.1%. In 2016, the global economy is forecast to grow by 3.6%. Back in July, the IMF had still expected to see global growth of 3.3% in 2015 and 3.8% in 2016.

While the IMF has made only minor revisions to its growth forecasts for industrialized economies, the growth prospects for some emerging economies have deteriorated significantly. The euro area and US economies are expected to grow by 1.5% and 2.5% respectively in 2015, and thus faster than previously assumed, while according to the IMF forecast China could witness the lowest level of growth in decades. Given the fall in the oil price, Russia and Brazil may even face prolonged recessions.

According to the IMF, the goal of ensuring strong, consistent global growth would be difficult to achieve. Furthermore, the risks to growth had risen compared with just a few months ago. This was mainly due to the economic transformation in China, with all its attendant problems, the sharp fall in commodities prices, and the turnaround now apparent in US interest rate policy.

Irrespective of the aforementioned developments, global demographic developments represent one of the most serious challenges facing the world. The dynamic growth in the world's population, together with an unprecedented increase in the elderly share of the population and the sharp rise in the number of people with access to medical care, represent key factors which will shape the 21st century. This situation is accompanied by scientific and technological progress, which is opening up ever new possibilities in the fields of medicine, research, diagnostics and life science.

These developments will lead not only to an increase in the numbers of clinical diagnostics tests to be performed, but will also result in new, unique business opportunities for which STRATEC is optimally positioned with its automation solutions and on which it will continue to focus its strategy and operations.

For the reasons outlined above, global economic risks such as the current slowdown in growth in China only have a limited impact on STRATEC's business performance and business model. Moreover, long-term supply agreements with our customers minimize the potential implications for STRATEC.

Industry and market data: Based on different estimates, in-vitro diagnostics (IVD) will continue to show average global growth of around 4% to 5% in the years until 2018 and 2020 respectively. Some regions, such as the BRIC states, are growing significantly faster, while other regions, such as Europe, are not expected to show any growth. Similar developments can be seen in the various IVD segments. While some areas in which STRATEC consciously does not operate, such as blood sugar self-testing, are expected to decline significantly, other segments are expected to show very strong growth in future as well. STRATEC plans to continue benefiting to a disproportionate extent from these growth rates by deliberately tracking down and developing projects in high-growth niches. The company currently has both customer projects and proprietary platform solutions in development for several of these sub-segments.

The US still represent a special case. While cost savings could have a slightly negative impact on the test volumes handled at laboratories, overall test volumes are nevertheless expected to rise due to the growing number of people with health insurance. On the one hand, the number of people insured has most recently risen slightly due to lower unemployment rates and is expected to remain stable until 2018. On the other hand the Affordable Care Act (Obamacare) is expected to substantially increase the number of people insured from around 217 million in 2015 to around 235 million.

Even though the diagnostics, pharmaceuticals and healthcare industry repeatedly witnesses short-term periods of consolidation at individual market players due to corporate takeovers and new technological development possibilities, several underlying factors will guarantee sustainable growth in future as well:

• Increasing market regulation, leading manual and semi-automated, in some cases homegrown test methods to be displaced by fully automated processes – whose lifecycles are thus simultaneously extended
• Development and expansion in healthcare systems, particularly in developing and emerging economies (especially in BRIC states)
• Expansion in global infrastructure and thus improved access to medical care
• Rapidly growing niche markets due to new medical discoveries and new diagnostic possibilities
• Newly developed diagnostics tests in all major areas of application, such as for oncology, sexually transmitted diseases, or hospital bugs
• Demographic developments (growing global population, increasingly elderly population with growing diagnostics requirements).

Report on Forecasts and other Statements Concerning the Company's Expected Development

STRATEC aims to generate permanent, sustainable growth in all business divisions. We are building on innovative solutions enabling our customers to serve their markets with high-quality products. Alongside the activities within our group of companies, we are also relying on further growth in our target markets, especially in the field of in-vitro diagnostics and on the continuing positive trend towards outsourcing at our partners and potential customers.

The Group's performance in the first nine months confirms the current forecast for 2015, according to which STRATEC expects to generate slight year-on-year sales growth at around the growth rates reported to date in 2015. As a result of the developments outlined above, the EBIT margin is expected to be above the level reported for the ninemonth period.

Although individual customers have slightly reduced their forecasts for the remainder of the financial year and for 2016 to account for the current dip in turnover figures in Asia, we can confirm our valid mid-term financial forecast. This provides for average annual sales growth of eight to twelve percent through to 2017 based on the figures for the 2013 financial year (1 128.0 million) and for this to be accompanied by increasing profitability. We expect figures to fall below or exceed this range in individual years.

Due to the immense debt accumulated by some countries and economic regions and the resultant potential implications (debt crisis), movements in currency markets, and volatile developments in individual economic regions, the level of budgeting reliability remains low for all industries, and for the global economy as a whole. This situation continues to harbor risks for STRATEC's customers and suppliers, as a result of which STRATEC also faces economic risks. The ongoing difficult economic climate also means that STRATEC continues to face increased market risk.

Apart from this, since the assessment of the company's situation provided on March 31, 2015 upon the compilation of the Annual Report for the 2014 financial year, no new information has arisen which could lead to any change in our assessment of the company's expected development.

Opportunity and Risk Report

We analyze and evaluate the risks facing the company and its business environment within the framework of our risk management system, which has been established as an early warning risk identification system. Furthermore, this system also includes an internal control system (IKS) and a compliance system to ensure compliance with the relevant legal and industry-specific requirements.

STRATEC's business activities basically focus on sustainability and responsible behavior. In future, the company will document this in a sustainability report.

Apart from the factors outlined in the "Report on forecasts and other statements concerning the company's expected development", we do not see any changes compared with the risks and opportunities identified in the Group Management Report for the 2014 financial year dated March 31, 2015. Details of our risk management system and our company's specific opportunity and risk profile can be found in Section D "Opportunity and Risk Report" of our 2014 Group Management Report. Information about our use of financial instruments can be found in Section F of the 2014 Group Management Report.

Consolidated Balance Sheet

as of September 30, 2015 of STRATEC Biomedical AG

Assets in D thousands	09.30.2015	12.31.2014
Non-current Assets
Goodwill	5,040	4,785
Other intangible assets	25,992	25,477
Property, plant and equipment	17,751	15,954
Interests in associates	183	263
Deferred tax assets	1,254	1,260
	50,220	47,739
Current Assets
Raw materials and supplies	10,938	8,065
Unfinished products, unfinished services	6,899	6,591
Finished products and goods	2,151	3,410
Trade receivables	20,667	18,961
Future receivables from construction contracts	10	1,644
Receivables from associates	23	23
Income tax receivables	5,526	2,635
Other receivables and other assets	1,749	1,167
Other financial assets	924	877
Cash and cash equivalents	54,725	46,636
	103,612	90,009
Total Assets	153,832	137,748

Shareholders' Equity and Debt in D thousands	09.30.2015	12.31.2014
Shareholders' Equity
Share capital	11,846	11,795
Capital reserve	19,801	18,129
Revenue reserves	88,139	80,478
Other equity	3,958	1,649
	123,744	112,051
Debt
Non-current debt
Non-current financial liabilities	3,892	4,484
Pension provisions	61	61
Deferred taxes	6,749	5,565
	10,702	10,110
Current debt
Current financial liabilities	1,367	2,449
Trade payables	4,564	2,814
Liabilities to associates	23	41
Other current liabilities	10,270	7,140
Current provisions	1,707	1,732
Income tax liabilities	1,455	1,411
	19,386	15,587
Total Shareholders' Equity and Debt	153,832	137,748

Consolidated Statement of Comprehensive Income

for the Period from July 1 to September 30, 2015 of STRATEC Biomedical AG

in D thousands	07.01. –09.30.2015	07.01. –09.30.2014
Sales	37,188	36,228
Cost of sales	-23,036	-23,052
Gross profit	14,152	13,176
Research and development expenses	-2,234	-2,559
Information only: Total research and development expenses	-4,971	-5,048
Information only: Capitalized research and development expenses	2,737	2,489
Sales-related expenses	-1,708	-1,220
General administrative expenses	-2,888	-2,398
Other operating income and expenses	-73	-231
EBIT	7,249	6,768
Net financial expenses	32	-34
Earnings before taxes (EBT)	7,281	6,734
Current tax expenses	-1,136	-1,599
Deferred tax expenses	-36	91
Consolidated net income	6,109	5,226
Items that may be subsequently reclassified to profit or loss
Currency translation differences from translation of foreign operations	-1,341	638
Comprehensive income	4,768	5,864
Earnings per share in 3	0.52	0.44
No. of shares used as basis	11,814,768	11,778,966
Earnings per share, diluted, in 3	0.51	0.44
No. of shares used as basis, diluted	11,904,166	11,843,051

Consolidated Statement of Comprehensive Income

for the Period from January 1 to September 30, 2015 of STRATEC Biomedical AG

in D thousands	07.01. –09.30.2015	07.01. –09.30.2014
Sales	107,200	105,278
Cost of sales	-67,573	-69,518
Gross profit	39,627	35,760
Research and development expenses	-5,598	-5,506
Information only: Total research and development expenses	-15,785	-14,347
Information only: Capitalized research and development expenses	10,187	8,841
Sales-related expenses	-4,972	-4,217
General administrative expenses	-8,196	-8,208
Other operating income and expenses	-1,626	-787
EBIT	19,235	17,042
Net financial expenses	186	-113
Earnings before taxes (EBT)	19,421	16,929
Current tax expenses	-2,328	-2,569
Deferred tax expenses	-1,177	-210
Consolidated net income	15,916	14,150
Items that may be subsequently reclassified to profit or loss
Currency translation differences from translation of foreign operations	2,309	1,039
Comprehensive income	18,225	15,189
Earnings per share in 3	1.35	1.20
No. of shares used as basis	11,796,415	11,765,491
Earnings per share, diluted, in 3	1.34	1.20
No. of shares used as basis, diluted	11,906,174	11,818,081

Consolidated Statement of Changes in Equity

for the Period from January 1 to September 30, 2014 of STRATEC Biomedical AG

in D thousands	Share capital	Capital reserve
Balance at 01.01.2014	11,770	17,219
Equity transactions with owners
Dividend payment
Issue of subscription shares from stock option programs, less costs of capital issue after taxes	21	554
Allocations due to stock option plans		200
Total comprehensive income
Balance at 09.30.2014	11,791	17,973

for the Period from January 1 to September 30, 2015 of STRATEC Biomedical AG

in D thousands	Share capital	Capital reserve
Balance at 01.01.2015	11,795	18,129
Equity transactions with owners
Dividend payment
Issue of subscription shares from stock option programs, less costs of capital issue after taxes	51	1,424
Allocations due to stock option plans / Employee stock option programs		248
Total comprehensive income
Change in scope of consolidation
Balance at 09.30.2015	11,846	19,801

Currency translation Group equity
	Pension plans	Treasury stock	Free revenue reserves	Accumulated net income
-18 654		-212	19,392	48,374
				-7,055
1,039				14,150
-18 1,693		-212	19,392	55,469

	Other equity		Revenue reserves
Group equity	Currency translation	Pension plans	Treasury stock	Free revenue reserves	Accumulated net income
112,051	1,928	-67	-212	19,392	61,086
-8,248					-8,248
1,475
248
18,225	2,309				15,916
-7					-7
123,744	4,237	-67	-212	19,392	68,747

Consolidated Cash Flow Statement

for the Period from January 1 to September 30, 2015 of STRATEC Biomedical AG

in D thousands	01.01.–09.30.2015	01.01. –09.30.2014
Consolidated net income (after taxes)	15,916	14,150
Depreciation and amortization	4,133	5,759
Current income tax expenses	2,328	2,569
Income taxes paid less income taxes received	-5,291	-2,188
Financial income	-273	-88
Financial expenses	134	144
Interest paid	-113	-142
Interest received	270	88
Other non-cash expenses	763	916
Other non-cash income	-94	-1,717
Cash flow	17,773	19,491
Change in deferred taxes through profit or loss	1,177	210
Profit on disposals of non-current assets	-18	-56
Increase (previous year: decrease) in inventories, trade receivables and other assets	-2,069	1,083
Increase in trade payables and other liabilities	4,595	5,007
Inflow of funds from operating activities	21,458	25,735
Incoming payments from disposals of non-current assets
Property, plant and equipment	143	165
Outgoing payments for investments in non-current assets
Intangible assets	-2,480	-4,489
Property, plant and equipment	-2,994	-1,356
Outflow of funds for investing activities	-5,331	-5,680
Incoming payments from taking up of financial liabilities	2,000	0
Outgoing payments for repayment of financial liabilities	-3,948	-1,467
Incoming payments for issues of shares for employee stock option programs	1,475	575
Dividend payment	-8,248	-7,055
Outflow of funds for financing activities	-8,721	-7,947
Cash-effective change in cash and cash equivalents	7,406	12,108
Cash and cash equivalents at start of period	46,636	20,734
Change in scope of consolidation	79	0
Impact of exchange rate movements	604	1,769
Cash and cash equivalents at end of period	54,725	34,611

Notes to the Group Interim Report

for the Period from January 1 to September 30, 2015 of STRATEC Biomedical AG

Summary of principal accounting and valuation methods

The consolidated financial statements of STRATEC Biomedical AG as of December 31, 2014 were prepared in accordance with the International Financial Reporting Standards (IFRS) as adopted by the EU valid at the balance sheet date. In the interim report as of September 30, 2015, which has been prepared on the basis of International Accounting Standard (IAS) 34 "Interim Financial Reporting", application has been made of the same accounting methods as in the consolidated financial statements for the 2014 financial year. One exception applies to the first-time inclusion in the scope of consolidation of STRATEC Services AG, Beringen, Switzerland, a company founded in the 2014 financial year. The implications of the first-time full consolidation of this company for the net asset, financial and earnings position of the STRATEC Group are of subordinate significance. Application has also been made of all interpretations of the International Financial Reporting Interpretations Committee (IFRIC) with binding effect as of September 30, 2015.

There were no indications of any potential impairment in goodwill at the balance sheet date.

The interim reports are neither audited, nor subject to an audit review by the group auditor, Ebner Stolz GmbH & Co. KG Wirtschaftsprüfungsgesellschaft Steuerberatungsgesellschaft, Stuttgart.

Reference is made to the consolidated financial statements of STRATEC Biomedical AG as of December 31, 2014 with regard to further information concerning the individual accounting and valuation methods applied.

The Group's currency is the euro. Unless otherwise indicated, all amounts have been stated in thousand euros (1 thousand).

Segment disclosures

Apart from the first-time inclusion of STRATEC Services AG, Beringen, Switzerland, in the "Instrumentation" segment, there have been no changes in segmentation compared with the consolidated financial statements as of December 31, 2014.

Segment data by operating segment for the period from January 1 to September 30, 2015

in 1 thousands	Instrumentation	All other segments	Reconciliation	Total
Sales	128,429	9,390	-30,619	107,200
EBIT	18,735	1,036	-536	19,235
Assets	166,541	8,053	-20,762	153,832

Segment data by operating segment for the period from January 1 to September 30, 2014

in 1 thousands	Instrumentation	All other segments	Reconciliation	Total
Sales	109,177	5,061	-8,960	105,278
EBIT	17,378	-293	-43	17,042
Assets	141,036	6,179	-16,998	130,217

The breakdown of sales by geographical region represents the distribution of the STRATEC Group's products. As the customers of the STRATEC Group generally supply their country outlets and customers from their own central distribution centers, however, this breakdown of sales does not represent the geographical distribution of the final operating locations of the STRATEC Group's analyzer systems.

Sales can be broken down by geographical regions (customer locations) as follows:

in 1 thousands	Germany	EU	Other	Total
January – September 2015	17,052	42,644	47,504	107,200
	15.9%	39.8%	44.3%	100.0%
in 1 thousands	Germany	EU	Other	Total
January – September 2014	12,771	44,757	47,750	105,278
	12.1%	42.5%	45.4%	100.0%

Research and development expenses

Research and development expenses not fulfilling the capitalization criteria set out in IAS 38 (Intangible Assets) amounted to 1 5.6 million in the first nine months of the 2015 financial year (previous year: 1 5.5 million) and mainly involve personnel and material expenses. The STRATEC Group invested a total of 1 15.8 million in research and development in the first nine months of the 2015 financial year (previous year: 1 14.3 million). Due to the modification in the recognition of gross development expenses in the statement of comprehensive income at the end of the 2014 financial year, the comparative figures in the interim report have also been adjusted accordingly.

Shareholders' equity

The development in shareholders' equity at the STRATEC Group has been presented in the consolidated statement of changes in equity on Pages 13 and 14. The number of ordinary shares issued by STRATEC Biomedical AG as of September 30, 2015 amounts to 11,846,595.

Based on the resolution adopted by the Annual General Meeting on May 22, 2015, on Friday, August 28, 2015 STRATEC converted its stock of shares at a ratio of 1:1 from bearer shares with a nominal amount of 1 1.00 to registered shares in the form of no-par shares (shares with no nominal amount).

Disclosures on the volume of treasury stock and on subscription rights held by members of the company's executive and supervisory bodies and its employees pursuant to § 160 (1) Nos. 2 and 5 of the German Stock Corporation Act (AktG)

STRATEC Biomedical AG owned a total of 12,223 treasury stock at the interim balance sheet date. This corresponds to a prorated amount of 1 12,223.00 of the company's share capital and to a 0.10% share of its equity.

Stock option programs

Members of the Board of Management / Managing Directors and employees held the following numbers of subscription rights (share option rights) at the interim balance sheet date:

in 1 thousands	Board of Management/ Managing Directors	Employees	Total
Outstanding on 01.01.2015	171,000	99,500	270,500
Issued	3,000	8,550	11,550
Exercised	27,500	23,650	51,150
Lapsed	0	0	0
Forfeited	0	500	0
Outstanding on 09.30.2015	146,500	83,900	230,900

Of the stock option rights granted in the nine months, none related to members of the Board of Management (previous year: 40,000), 3,000 to managing directors at subsidiaries (previous year: 0), and 8,550 to employees (previous year: 9,050).

Furthermore, 27,500 stock option rights were exercised by members of the Board of Management in the first nine months (previous year: 15,000). As in the previous year, the managing directors at subsidiaries did not exercise any stock option rights in this period. Employees exercised 23,650 stock option rights (previous year: 6,100). To service the stock option rights thereby exercised, a total of 51,150 shares were created from conditional capital (previous year: 21,100).

As in the previous year, no stock option rights lapsed in the period under report. A total of 500 of the employee stock options was forfeited in the period under report (previous year: 0).

Employees

Including temporary employees the STRATEC Group had a total workforce of 573 employees as of September 30, 2015 (previous year: 554).

Major events after the interim reporting date

No events of particular significance with material implications for the business performance of our Group have occurred since the interim balance sheet date.

Responsibility statement

To the best of our knowledge, and in accordance with the applicable reporting principles for interim financial reporting, the interim consolidated financial statements give a true and fair view of the assets, liabilities, financial position and profit or loss of the Group, and the interim management report of the Group includes a fair review of the development and performance of the business and the position of the Group, together with a description of the principal opportunities and risks associated with the expected development of the Group in the remainder of the financial year.

Additional Information

Financial Calendar

October 28, 2015	Interim Report as of September 30, 2015
November 24, 2015	German Equity Forum, Frankfurt / Main, Germany – Analysts' conference –

Furthermore, based on current planning, STRATEC will be taking part in the following capital market conferences in 2015:

November 2015	HSBC Healthcare Day 2015, Frankfurt / Main, Germany LBBW German Company Day 2015, London, UK Jefferies 2015 Global Healthcare Conference, London, UK
December 2015	Berenberg Bank European Conference, Pennyhill Park, UK

Partially incomplete/subject to amendment

About STRATEC

STRATEC Biomedical AG designs and manufactures fully automated analyzer systems for its partners in the fields of clinical diagnostics and biotechnology. These partners market such systems, in general together with their own reagents, as system solutions to laboratories, blood banks and research institutes around the world. The company develops its products on the basis of its own patented technologies.

Shares in the company (ISIN: DE000STRA555) are traded in the Prime Standard segment of the Frankfurt Stock Exchange and are listed in the TecDAX select index of the German Stock Exchange.

Further information about STRATEC is available on the internet at www.stratec.com.

Imprint

Published by

STRATEC Biomedical AG Gewerbestr. 37 75217 Birkenfeld Germany

Investor Relations

Andreas Künzel Phone: +49 7082 7916-185 Fax: +49 7082 7916-999 a.kuenzel@stratec.com

Phone: +49 7082 7916-0 Fax: +49 7082 7916-999 info@stratec.com www.stratec.com

Corporate Communications

Andre Loy Phone: +49 7082 7916-190 Fax: +49 7082 7916-999 a.loy@stratec.com

Concept and Design Whitepark GmbH & Co., Hamburg, Germany Text STRATEC Biomedical AG, Birkenfeld, Germany

NOTICE

Forward-looking statements involve risks: This interim report contains various statements concerning the future performance of STRATEC. These statements are based on both assumptions and estimates. Although we are convinced that these forward-looking statements are realistic, we can provide no guarantee of this. This is because our assumptions involve risks and uncertainties which could result in a substantial divergence between actual results and those expected. It is not planned to update these forward-looking statements.

This interim report contains various disclosures of an economic nature that do not form part of the relevant accounting requirements. These disclosures are to be viewed as a supplement to, rather than as a substitute for the disclosures made in accordance with IFRS.

Discrepancies may arise throughout this interim report on account of mathematical rounding up or down in the course of addition.

This interim report is also available in German.

STRATEC Biomedical AG

Gewerbestr. 37 75217 Birkenfeld Germany

Phone: +49 7082 7916-0 Fax: +49 7082 7916-999

info@stratec.com www.stratec.com